A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantigens have no or low immunogenicity. Here, a bi-adjuvant neoantigen nanovaccine (banNV) that codelivered a peptide neoantigen (Adpgk) with two adjuvants [Toll-like receptor (TLR)...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Adv
Main Authors: Ni, Qianqian, Zhang, Fuwu, Liu, Yijing, Wang, Zhantong, Yu, Guocan, Liang, Brian, Niu, Gang, Su, Ting, Zhu, Guizhi, Lu, Guangming, Zhang, Longjiang, Chen, Xiaoyuan
Format: Artigo
Jezik:Inglês
Izdano: American Association for the Advancement of Science 2020
Teme:
Research Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7080439/
https://ncbi.nlm.nih.gov/pubmed/32206706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aaw6071
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki